Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137338 | Leukemia Research | 2011 | 4 Pages |
Abstract
Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gail J. Roboz, Ellen K. Ritchie, Tania Curcio, Michael Samuel, Juliette Provenzano, Javier Segovia, Paul J. Christos, Susan Mathew, Sandra Allen-Bard, Eric J. Feldman,